3 Drugs Stocks On The Rise
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.
All three major indices are trading up today with the
Dow Jones Industrial Average
(
^DJI
) trading up 171 points (1.0%) at 18,028 as of Monday, March 9, 2015, 1:50 PM ET. The NYSE advances/declines ratio sits at 1,589 issues advancing vs. 1,440 declining with 142 unchanged.
The Drugs industry currently sits down 0.7% versus the S&P 500, which is up 0.5%. Top gainers within the industry include
(
), up 1.4%, and
Teva Pharmaceutical Industries
(
), up 0.9%. On the negative front, top decliners within the industry include
(
), down 5.4%, and
(
), down 2.3%.
TheStreet would like to highlight 3 stocks pushing the industry higher today:
3.
(
) is one of the companies pushing the Drugs industry higher today. As of noon trading, Bristol-Myers Squibb Company is up $1.20 (1.8%) to $66.32 on average volume. Thus far, 3.7 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 6.3 million shares. The stock has ranged in price between $65.07-$66.40 after having opened the day at $65.23 as compared to the previous trading day's close of $65.12.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company has a market cap of $109.8 billion and is part of the health care sector. Shares are up 10.3% year-to-date as of the close of trading on Friday. Currently there are 9 analysts who rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 7 rate it a hold.
TheStreet Ratings rates
Bristol-Myers Squibb Company
as a
. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, weak operating cash flow and disappointing return on equity. Get the full
Bristol-Myers Squibb Company Ratings Report
now.
2. As of noon trading,
Valeant Pharmaceuticals International
(
) is up $5.36 (2.7%) to $204.08 on heavy volume. Thus far, 3.1 million shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 2.8 million shares. The stock has ranged in price between $195.20-$205.30 after having opened the day at $199.46 as compared to the previous trading day's close of $198.71.
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. Valeant Pharmaceuticals International has a market cap of $68.6 billion and is part of the health care sector. Shares are up 38.9% year-to-date as of the close of trading on Friday. Currently there are 11 analysts who rate Valeant Pharmaceuticals International a buy, no analysts rate it a sell, and 2 rate it a hold.
TheStreet Ratings rates
Valeant Pharmaceuticals International
as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, expanding profit margins and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full
Valeant Pharmaceuticals International Ratings Report
now.
1. As of noon trading,
(
) is up $3.51 (1.2%) to $293.43 on average volume. Thus far, 1.9 million shares of Actavis exchanged hands as compared to its average daily volume of 2.8 million shares. The stock has ranged in price between $287.62-$293.91 after having opened the day at $290.08 as compared to the previous trading day's close of $289.92.
Actavis plc develops, manufactures, and sells generic, brand, and biosimilar pharmaceuticals. It offers over-the-counter products. The company also provides biosimilar products in women's health, oncology, and other therapeutic categories. Actavis has a market cap of $78.7 billion and is part of the health care sector. Shares are up 12.6% year-to-date as of the close of trading on Friday. Currently there are 17 analysts who rate Actavis a buy, no analysts rate it a sell, and 1 rates it a hold.
TheStreet Ratings rates
Actavis
as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full
now.
If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
null